How should I manage mild hyperkalemia (potassium 5.3 mmol/L) in a patient with stage 3a chronic kidney disease (eGFR ≈ 48 mL/min/1.73 m²) who is taking lisinopril?

Management of Mild Hyperkalemia (K+ 5.3) in CKD Stage 3a on Lisinopril

Continue the lisinopril and manage the hyperkalemia through dietary modification, close monitoring, and consideration of potassium binders rather than stopping or reducing the ACE inhibitor. Your patient's potassium of 5.3 mmol/L falls into the mild-moderate range (4.9-5.5 mmol/L) where RASi continuation is explicitly recommended by KDIGO 2024 guidelines 1.

Why Continue Lisinopril

The KDIGO 2024 guidelines are unequivocal: hyperkalemia associated with RASi can often be managed by measures to reduce serum potassium levels rather than decreasing the dose or stopping RASi 1. This is critical because:

• Your patient has diabetes with CKD and improved albuminuria (UACR 19, down from 66), indicating the lisinopril is providing renal protection
• Discontinuing or reducing RASi is associated with increased mortality, heart failure hospitalizations, and progression to end-stage kidney disease 2
• The FDA label for lisinopril acknowledges hyperkalemia risk but emphasizes monitoring rather than automatic discontinuation 3

Immediate Management Steps

1. Dietary Interventions (First-Line)

• Counsel on avoiding high-potassium foods (bananas, oranges, tomatoes, potatoes, spinach)
• Eliminate potassium supplements and salt substitutes (as you've already noted)
• Restrict dietary potassium to <2-3 grams daily
• Increase dietary fiber intake

2. Medication Review

• Continue dapagliflozin (SGLT2i) - this actually helps with potassium management and provides cardio-renal protection 1
• Verify patient is not taking NSAIDs, which worsen hyperkalemia
• Check for any hidden potassium sources in supplements

3. Monitoring Protocol

• Recheck BMP in 2-4 weeks (not 6-8 weeks as initially planned) per KDIGO recommendations for RASi-associated hyperkalemia 1
• If K+ remains 4.9-5.5 mmol/L: continue current management with monthly monitoring until stable
• If K+ rises to >5.5 mmol/L: proceed to pharmacologic intervention

When to Consider Potassium Binders

If dietary measures fail and K+ remains >5.0 mmol/L or trends upward, consider adding:

• Patiromer or sodium zirconium cyclosilicate (SZC) - newer agents with better tolerability and evidence base 4, 5
• These allow continuation of optimal-dose RASi while maintaining normokalemia
• Avoid sodium polystyrene sulfonate (Kayexalate) for chronic management due to adverse effects and limited evidence 5

When to Reduce or Stop Lisinopril

Per KDIGO 2024, consider dose reduction or discontinuation ONLY if 1:

• K+ >5.5 mmol/L despite medical treatment (dietary changes + potassium binders)
• Symptomatic hyperkalemia (muscle weakness, palpitations, ECG changes)
• eGFR falls below 15 mL/min/1.73 m² with uremic symptoms

Your patient does not meet any of these criteria.

Common Pitfalls to Avoid

1. Premature RASi discontinuation: This is the most common error and worsens long-term outcomes 2, 6
2. Waiting too long to recheck potassium: The 6-8 week interval is too long for someone with trending hyperkalemia on RASi
3. Ignoring the improved albuminuria: Your patient's UACR dropped from 66 to 19 - the lisinopril is working
4. Overlooking SGLT2i benefits: Continue dapagliflozin as it provides independent cardio-renal protection and doesn't worsen hyperkalemia 1

Nephrology Referral Context

Your nephrology referral is appropriate for CKD management, but inform them you're maintaining the lisinopril per KDIGO guidelines. Nephrology can help with:

• Long-term hyperkalemia management strategies
• Consideration of adding a non-steroidal MRA (finerenone) once K+ is consistently <4.8 mmol/L 1
• CKD progression monitoring

Practical Algorithm

K+ 5.3 mmol/L on lisinopril:
├─ Continue lisinopril at current dose
├─ Implement dietary potassium restriction
├─ Recheck BMP in 2-4 weeks
    ├─ K+ <5.0: Monitor monthly × 3, then quarterly
    ├─ K+ 5.0-5.5: Continue diet, consider potassium binder
    └─ K+ >5.5: Add potassium binder (patiromer or SZC)
        ├─ If controlled: Continue all medications
        └─ If uncontrolled despite binder: Reduce lisinopril dose by 50%

The key message: Your concern is understandable, but K+ 5.3 mmol/L is manageable without stopping the lisinopril, which would harm your patient's long-term cardio-renal outcomes.